Parkinson’s Disease Screening Library | Targeted and Focused Screening Libraries | Screening Libraries

Parkinson’s disease is the second most prevalent neurodegenerative disorder, affecting millions of people worldwide. Although significant progress has been made in understanding its molecular mechanisms, current therapies mainly address symptoms rather than control disease progression. This gap highlights the urgent need for novel therapeutic strategies.

Our cheminformatics team has developed a proprietary Parkinson’s Disease Screening Library to support CNS drug discovery and neurodegeneration research. It features more than 18,300 small molecules linked to adenosine-related targets, histamine receptors, and other pathological mechanisms associated with neurodegeneration.

Every compound was selected from our in-stock HTS Compound Collection using an advanced cheminformatics workflow to ensure structural diversity, biological relevance, and screening suitability. This Screening Library spans molecular entities involved in neuroinflammation, oxidative stress, and motor dysfunction pathways central to Parkinson’s disease progression. Notably, many targets are connected directly or indirectly to α-synuclein, a key protein in Parkinson’s disease pathogenesis.

The compound selection can be customized based on your requirements. Cherry picking is available.

Please, contact us at orders@lifechemicals.com for any additional information and price quotations.

Further exploring our related products will make your search even more rewarding:

Representative screening compounds from the Parkinson’s Disease Screening Library

Background information

Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to motor symptoms such as resting tremor, rigidity, bradykinesia, and postural instability [1]. Non-motor symptoms, including cognitive impairment, depression, anxiety, sleep disturbances, and autonomic dysfunction, further complicate the disease, significantly impacting patients’ quality of life [2]. PD affects approximately 1–2% of individuals over 60 years, with prevalence increasing with age [3].

The pathogenesis of PD is multifactorial, involving protein misfolding, mitochondrial dysfunction, oxidative stress, and neuroinflammation [4]. A hallmark is the accumulation of misfolded α-synuclein, which forms Lewy bodies, disrupting neuronal function and contributing to neurodegeneration [5]. Mitochondrial dysfunction, particularly impaired complex I activity, leads to energy deficits and increased reactive oxygen species, exacerbating neuronal damage [6]. Neuroinflammation, driven by microglial activation, amplifies neuronal loss through pro-inflammatory pathways [7]. Genetic factors, including mutations in LRRK2, SNCA, and GBA genes, play a significant role in both familial and sporadic PD [8].

Traditional treatments, like levodopa, alleviate motor symptoms but do not modify disease progression, often causing complications, such as dyskinesias [9]. Over the past two years, novel therapeutic targets have emerged. Inhibiting monoamine oxidase B (MAO-B), which metabolizes dopamine and generates oxidative byproducts, remains a key strategy to enhance dopaminergic signaling and reduce oxidative stress [10]. Recent research highlights the gut-brain axis, with a-synuclein misfolding in the gut potentially initiating PD pathology via the vagus nerve, suggesting that microbiota-modulating therapies [11] may be warranted. Targeting lysosomal function, particularly GBA1-associated pathways, enhances alpha-synuclein clearance and is a promising focus, with clinical trials exploring GBA activators [12]. Neuroinflammation is another critical target, with novel approaches inhibiting NLRP3 inflammasome activation and TREM2-mediated microglial responses to reduce neuronal damage [13]. Additionally, mitochondrial-targeted antioxidants and mitophagy enhancers, such as urolithin A, are being investigated to restore mitochondrial function [14]. Also, gene therapies targeting LRRK2 mutations and antisense oligonucleotides to reduce a-synuclein expression have shown preclinical promise [15].

Figure 1. Overview of mechanisms of action for approved drugs against Parkinson’s disease.

Figure 1. Overview of mechanisms of action for approved drugs against Parkinson’s disease.

Compound selection

The Screening Library presented is based on the following targets selected for their ability to address α-synuclein-related pathology, either by directly inhibiting aggregation or modulating downstream effects, like inflammation and neuronal death, enabling a comprehensive approach to identifying effective Parkinson’s disease therapeutics:

Adenosine-related targets: Adenosine receptors (A1, A2a, A2b, A3) modulate neurotransmission and neuroinflammation. A2a receptor antagonists mitigate motor symptoms by enhancing dopaminergic signaling [16] and reducing neuroinflammation, which may decrease α-synuclein-induced neurotoxicity [17]. Adenosine kinase and adenosine deaminase regulate extracellular adenosine levels, promoting neuroprotection [18], which may mitigate α-synuclein aggregation [19]. Adenosine transporter 1 regulates adenosine availability, influencing neuroinflammatory responses associated with α-synuclein pathology [20].
Histamine receptors H1, H2, H3, and H4 regulate neuroinflammation and neuronal activity. H3 receptors modulate neurotransmitter release, potentially improving cognitive and motor functions. Their regulation of microglial activation can reduce inflammation-driven α-synuclein toxicity.
Enzymes and pathological targets: Dipeptidyl peptidase IV (DPP-IV) influences neuropeptide metabolism and may modulate inflammatory pathways linked to α-synuclein. Small-molecule aggregation inhibitors directly target misfolded α-synuclein, preventing toxic oligomer formation and Lewy body formation, hallmarks of Parkinson’s disease. Anti-inflammatory compounds and apoptosis modulators that cross the blood-brain barrier reduce neuroinflammation and neuronal loss, both of which are exacerbated by α-synuclein misfolding.

The first strategy focused on inhibiting α-synuclein (αS) aggregation, a hallmark of PD pathology. To this end, we employed a structure-based virtual screening methodology adapted from Horne et al. [21], in which docking simulations against αS fibrils were performed, followed by Tanimoto-based clustering and selection of centroids for experimental validation. Compounds from Life Chemicals' proprietary HTS Compound Collection were subsequently evaluated using a machine-learning model trained on aggregation assay data, prioritizing molecules that significantly prolonged the aggregation half-time (t₁/₂) relative to untreated controls. The Thet₁/₂ metric is a robust indicator of inhibitory potency in seeded αS aggregation assays; compounds that show≥2-fold increase are considered potent. This approach allowed for the identification of structurally diverse αS aggregation inhibitors.

In the second approach, ligand-based virtual screening was performed using 2D molecular fingerprints to identify compounds with high structural similarity to known modulators of PD-relevant targets. A Tanimoto similarity threshold of ≥0.85 was employed to ensure meaningful chemical resemblance. The reference dataset was derived from curated activity records in the ChEMBL database, encompassing compounds with confirmed bioactivity. This similarity-based filtering allowed us to enrich the selection with scaffolds possessing known mechanisms of action while maintaining chemical diversity.

In the third approach, compounds were selected from three of our focused screening libraries:

These libraries were pooled and subsequently filtered based on their predicted pharmacokinetic properties, specifically BBB permeability and CNS MPO score. BBB permeability was estimated using the quantitative model developed by Gupta et al. [22], which integrates physicochemical descriptors to predict passive translocation across the BBB. CNS MPO scores were calculated according to the framework proposed by Wager et al. [23], which combines six molecular properties (e.g., lipophilicity, molecular weight, topological polar surface area) to predict CNS drug-likeness. Only compounds achieving high scores on both metrics, indicative of favorable brain penetration and CNS-targeted pharmacodynamics, were retained for downstream analysis. These molecules represent candidates capable of modulating neurodegenerative processes at multiple mechanistic levels, including neuroinflammation, programmed cell death, and dysregulated proteostasis.

Figure 2. Schematic representation of PD biomarkers [24].

Figure 2. Schematic representation of PD biomarkers [24].

Reference:

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson's disease. Nat Rev Dis Primers. 2017 Mar 23;3:17013. Doi: 10.1038/nrdp.2017.13. PMID: 28332488.
Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006 Mar;5(3):235-45. doi: 10.1016/S1474-4422(06)70373-8. PMID: 16488379.
Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017 Aug;124(8):901-905. doi: 10.1007/s00702-017-1686-y. Epub 2017 Feb 1. PMID: 28150045.
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015 Aug 29;386(9996):896-912. doi: 10.1016/S0140-6736(14)61393-3. Epub 2015 Apr 19. PMID: 25904081.
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997 Aug 28;388(6645):839-40. doi: 10.1038/42166. PMID: 9278044.
Moon HE, Paek SH. Mitochondrial Dysfunction in Parkinson's Disease. Exp Neurobiol. 2015 Jun;24(2):103-16. doi: 10.5607/en.2015.24.2.103. Epub 2015 Jun 8. PMID: 26113789; PMCID: PMC4479806.
Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010 Mar;37(3):510-8. doi: 10.1016/j.nbd.2009.11.004. Epub 2009 Nov 10. PMID: 19913097; PMCID: PMC2823829.
Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, Bras J, Young E, von Coelln R, Simon-Sanchez J, Schulte C, Sharma M, Krohn L, Pihlstrom L, Siitonen A, Iwaki H, Leonard H, Faghri F, Gibbs JR, Hernandez DG, Scholz SW, Botia JA, Martinez M, Corvol JC, Lesage S, Jankovic J, Shulman LM, Sutherland M, Tienari P, Majamaa K, Toft M, Andreassen OA, Bangale T, Brice A, Yang J, Gan-Or Z, Gasser T, Heutink P, Shulman JM, Wood NW, Hinds DA, Hardy JA, Morris HR, Gratten J, Visscher PM, Graham RR, Singleton AB; 23andMe Research Team; System Genomics of Parkinson's Disease Consortium; International Parkinson's Disease Genomics Consortium. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019 Dec;18(12):1091-1102. doi: 10.1016/S1474-4422(19)30320-5. PMID: 31701892; PMCID: PMC8422160.
Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014 Apr 23-30;311(16):1670-83. doi: 10.1001/jama.2014.3654. PMID: 24756517.
Tan YY, Jenner P, Chen SD. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future. J Parkinsons Dis. 2022;12(2):477-493. doi: 10.3233/JPD-212976. PMID: 34957948; PMCID: PMC8925102.
Riegelman E, Xue KS, Wang JS, Tang L. Gut-Brain Axis in Focus: Polyphenols, Microbiota, and Their Influence on α-Synuclein in Parkinson's Disease. Nutrients. 2024 Jun 27;16(13):2041. doi: 10.3390/nu16132041. PMID: 38999791; PMCID: PMC11243524.
Skrahin A, Horowitz M, Istaiti M, Skrahina V, Lukas J, Yahalom G, Cohen ME, Revel-Vilk S, Goker-Alpan O, Becker-Cohen M, Hassin-Baer S, Svenningsson P, Rolfs A, Zimran A. GBA1-Associated Parkinson's Disease Is a Distinct Entity. Int J Mol Sci. 2024 Jun 28;25(13):7102. doi: 10.3390/ijms25137102. PMID: 39000225; PMCID: PMC11241486.
Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener. 2015 Oct 12;4:19. doi: 10.1186/s40035-015-0042-0. PMID: 26464797; PMCID: PMC4603346.
Xu J, Du W, Zhao Y, Lim K, Lu L, Zhang C, Li L. Mitochondria targeting drugs for neurodegenerative diseases-Design, mechanism and application. Acta Pharm Sin B. 2022 Jun;12(6):2778-2789. doi: 10.1016/j.apsb.2022.03.001. Epub 2022 Mar 10. PMID: 35755284; PMCID: PMC9214044.
Roberts WS, Price S, Wu M, Parmar MS. Emerging Gene Therapies for Alzheimer's and Parkinson's Diseases: An Overview of Clinical Trials and Promising Candidates. Cureus. 2024 Aug 16;16(8):e67037. doi: 10.7759/cureus.67037. PMID: 39286667; PMCID: PMC11405083.
Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 2006 Nov;29(11):647-54. doi: 10.1016/j.tins.2006.09.004. Epub 2006 Oct 9. PMID: 17030429.
Lim S, Chun Y, Lee JS, Lee SJ. Neuroinflammation in Synucleinopathies. Brain Pathol. 2016 May;26(3):404-9. doi: 10.1111/bpa.12371. PMID: 26940152; PMCID: PMC8028946.
Boison D. Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev. 2013 Apr 16;65(3):906-43. doi: 10.1124/pr.112.006361. PMID: 23592612; PMCID: PMC3698936.
Kachroo A, Schwarzschild MA. Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease. Ann Neurol. 2012 Feb;71(2):278-82. doi: 10.1002/ana.22630. PMID: 22367999; PMCID: PMC3292742.
Chang CP, Wu KC, Lin CY, Chern Y. Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases. J Biomed Sci. 2021 Oct 11;28(1):70. doi: 10.1186/s12929-021-00766-y. PMID: 34635103; PMCID: PMC8507231.
Horne, R.I., Andrzejewska, E.A., Alam, P. et al. Discovery of potent inhibitors of α-synuclein aggregation using structure-based iterative learning. Nat Chem Biol 20, 634-645 (2024). https://doi.org/10.1038/s41589-024-01580-x
Gupta, Mayuri et al. "The Blood-Brain Barrier (BBB) Score." Journal of medicinal chemistry vol. 62,21 (2019): 9824-9836.
Wager, Travis T et al. "Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes." ACS chemical neuroscience vol. 1,6 (2010): 420-34. doi:10.1021/cn100007x.
Arya, R., Haque, A. K., Shakya, H., Billah, M. M., Parvin, A., Rahman, M., Sakib, K. M., Faruquee, H. M., Kumar, V., & Kim, J. Parkinson's Disease: Biomarkers for Diagnosis and Disease Progression. International Journal of Molecular Sciences, 25(22), 12379. https://doi.org/10.3390/ijms252212379